New Findings on Long COVID and Dopamine Damage
A recent study has highlighted strong evidence linking long COVID to damage in dopamine-releasing neurons, as reported by scientists at the Centre for Addiction and Mental Health (CAMH). Published in eBioMedicine, the research reveals that this damage may help explain symptoms like fatigue, reduced motivation, slower movement, and memory issues.
Impact of Long COVID
Approximately 5% of the global population is believed to suffer from long COVID, including about 2 million Canadians. This condition can last for months and includes symptoms such as brain fog, low mood, and memory problems. Currently, there are no established treatments, partly due to a limited understanding of the underlying brain processes.
Study Methods
Researchers utilized positron emission tomography (PET) to examine dopamine neuron health in individuals with long COVID, comparing results to those of healthy participants. They discovered lower levels of a specific biological marker in all key areas of the striatum, which is involved in motivation, movement, and cognition. This reduction indicates a decreased density of dopamine nerve terminals.
Symptom Correlations
Distinct patterns of marker loss correlated with specific symptoms:
- Ventral striatum: Greater loss of motivation
- Dorsal putamen: Slower movement
- Caudate putamen: Memory difficulties
Insights from Previous Research
This study builds on previous findings indicating that long COVID is associated with high levels of brain inflammation, particularly in areas with many dopamine neurons. The correlation between inflammation and reduced dopamine neuron markers provides further evidence of potential neural damage.
Treatment Implications
These findings suggest a shift in how long COVID might be treated, proposing that it’s fundamentally a disorder of the brain’s dopamine system. There could be opportunities to repurpose existing medications that enhance dopamine function, offering a new avenue for treatment.
Voices of Experience
Susan Deuville, who has been affected by long COVID, expressed her hope that this research validates the experiences of many suffering from the condition, emphasizing the real and devastating impacts of long COVID.
Upcoming Clinical Trial
The research team is set to launch a clinical trial targeting dopamine functions in individuals with long COVID, in collaboration with the University Health Network (UHN). The primary aim is to assess whether modifying dopamine activity can alleviate symptoms such as memory issues, reduced motivation, and fatigue.
The study was supported by the Canadian Institutes of Health Research (CIHR), signaling a promising direction for understanding and addressing long COVID.
